Sonova Holding AG stock (CH0012549785): Hearing-care group updates guidance after FY 2024/ 25 results

Sonova Holding AG has reported its results for fiscal year 2024/25 and adjusted its outlook for the current year, providing fresh insights for investors in the global hearing-care market.

Swiss hearing-care specialist Sonova Holding AG has published its results for the 2024/25 financial year and updated its guidance for the current year, outlining trends in its audiological care and hearing instruments businesses, according to a company release dated 05/21/2025 and subsequent investor materials from Sonova as of 05/21/2025 and 06/04/2025Sonova media release as of 05/21/2025Sonova investor information as of 06/04/2025.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sonova
• Sector/industry: Hearing-care medical technology and audiological services
• Headquarters/country: Stäfa, Switzerland
• Core markets: Europe, North America, Asia-Pacific hearing-care markets
• Key revenue drivers: Hearing instruments, cochlear implants, audiological care retail network
• Home exchange/listing venue: SIX Swiss Exchange (ticker: SOON)
• Trading currency: Swiss franc (CHF)

Sonova Holding AG: core business model

Sonova Holding AG operates as a global hearing-care group focused on developing, manufacturing and distributing hearing instruments, cochlear implants and associated audiological services. The group positions itself across the full value chain, from research and product design to wholesale distribution and retail-based hearing-care services, with the aim of addressing different degrees and types of hearing loss in various age groups.

The company structures its activities into several operating segments, typically including a hearing instruments segment and an audiological care network, with a dedicated cochlear implant business integrated into its broader solutions portfolio, according to Sonova’s description of its business model in its annual reporting released on 05/21/2025Sonova annual report release as of 05/21/2025. This segmentation allows the group to combine technology development with direct consumer-facing services.

Sonova distributes its solutions through a combination of independent hearing-care professionals, chain retailers and its own branded audiological care outlets. In many markets, including the United States, the group works with audiologists and hearing aid dispensers to fit products, conduct diagnostics and provide follow-up care, which contributes to recurring revenue through device upgrades, batteries, accessories and professional services, based on its strategy presentations referenced in investor materials as of 06/04/2025Sonova investor presentation library as of 06/04/2025.

The group also emphasizes research and development in signal processing, miniaturization and connectivity features, such as Bluetooth-enabled devices and integration with consumer electronics. This technology focus aims to make hearing instruments more discreet and user-friendly, while increasing adoption rates in demographic segments that may historically have been reluctant to use hearing aids.

Main revenue and product drivers for Sonova Holding AG

A key revenue driver for Sonova Holding AG remains its hearing instruments business, which includes behind-the-ear, receiver-in-canal and in-the-ear devices under brands such as Phonak. These products are primarily sold through professionals who can program and fit the devices, and the segment’s performance is closely tied to demographic trends, reimbursement frameworks and consumer acceptance of premium features, as outlined in the company’s fiscal year 2024/25 documentation published on 05/21/2025Sonova FY 2024/25 release as of 05/21/2025.

The audiological care network, which includes company-owned and franchised hearing-care outlets, provides another significant revenue stream. This network enables Sonova to capture value at the point of sale and throughout the device life cycle via fitting, follow-up visits and potential upgrades. In several European markets and in North America, the group has expanded its footprint through acquisitions and organic roll-outs, which has increased its direct exposure to end-users according to investor updates as of 06/04/2025Sonova investor information as of 06/04/2025.

Sonova’s cochlear implant activities provide advanced solutions for patients with severe to profound hearing loss who receive limited benefit from traditional hearing instruments. While smaller than the hearing aids business, the cochlear implant segment contributes technological expertise and can support cross-selling opportunities through shared clinical relationships, according to the company’s segment commentary in its 2024/25 reporting dated 05/21/2025Sonova annual reporting overview as of 05/21/2025.

Geographically, revenue is spread across Europe, the Americas and Asia-Pacific, with the United States representing a strategically important market because of its size, private-pay dynamics and role as a test bed for new technology adoption. The group notes that currency movements, reimbursement changes and competitive pricing all influence reported revenue and margin trends across these regions, as highlighted in its guidance commentary released on 05/21/2025Sonova outlook update as of 05/21/2025.

Conclusion

Sonova Holding AG provides investors with exposure to the global hearing-care market through a combination of hearing instruments, cochlear implants and audiological services. The company’s fiscal year 2024/25 reporting and updated outlook from 05/21/2025 underline the importance of demographic trends, technology innovation and retail execution for future performance. For US-focused portfolios, Sonova’s role as a supplier and service provider in the American hearing-care landscape may be relevant, even though the primary listing is in Switzerland. As with other medical technology and healthcare service names, revenue growth, margin development, reimbursement conditions and competitive dynamics remain key variables that investors are likely to monitor over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.